Catherine McCulley
Nurse Practitioner · Sioux Falls, SDNPI 1881235471
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 243 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Mylan Specialty L.p. at 25.3% of the total. Reporting peaked in 2022 at $1,064 and has fallen 53.6% since, to $493 in 2025. Among nurse practitioner clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$1K
- Harmony Biosciences LLC$399
- Grifols USA, LLC$351
- Boehringer Ingelheim$295
- Baxter Healthcare$249
- Electromed, Inc.$248
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,42497%
- Education$1283%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 62 | $1,151 |
| Harmony Biosciences LLC | 24 | $399 |
| Grifols USA, LLC | 18 | $351 |
| Boehringer Ingelheim | 9 | $295 |
| Baxter Healthcare | 13 | $249 |
| Electromed, Inc. | 17 | $248 |
| United Therapeutics Corporation | 5 | $213 |
| Daiichi Sankyo Inc. | 22 | $204 |
| AbbVie | 11 | $194 |
| Insmed, Inc. | 11 | $160 |
| Biohaven Pharmaceuticals, Inc. | 4 | $158 |
| Amgen | 4 | $149 |
| GSK | 5 | $91 |
| Philips North America LLC | 4 | $83 |
| Regeneron Healthcare Solutions, Inc. | 4 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $65 |
| Pfizer | 2 | $51 |
| AstraZeneca | 3 | $50 |
| Viatris Specialty LLC | 2 | $49 |
| Bayer | 2 | $43 |
| Almatica Pharma LLC | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Optinose US, Inc. | 1 | $20 |
| Sanofi | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYVASO$124
- NURTEC ODT$122
- Tavneos$112
How this compares
$4,552 in reported general payments places this provider in the 95th percentile of 504 nurse practitioner providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $94,144 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $30,481 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $11,869 |
| OzempicSemaglutide | 12 | $10,906 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,754 |
| Arnuity ElliptaFluticasone Furoate | 19 | $5,251 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $4,539 |
| Budesonide | 32 | $2,718 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $1,521 |
| Np ThyroidThyroid,pork | 27 | $1,337 |
| Liothyronine Sodium | 31 | $1,293 |
| Ventolin HfaAlbuterol Sulfate | 12 | $765 |
| Gabapentin | 34 | $659 |
| SynthroidLevothyroxine Sodium | 12 | $628 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $91 | $135,630230 claims |
| Boehringer IngelheimStiolto Respimat | $295 | $11,86919 claims |
| AbbVieSynthroid | $194 | $62812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 504 nurse practitioner providers in South Dakota.
Other nurse practitioner in Sioux Falls
- Jamie BuschSioux Falls$60K
- Jessica SlabaSioux Falls$41K
- Christopher NelsonSioux Falls$35K
- Katherine EricsonSioux Falls$13K
- Gabrielle PriceSioux Falls$5K
- Jacqueline KelleySioux Falls$5K
- Jessica YoshinoSioux Falls$5K
- Heather MitzelSioux Falls$5K
- Tiffanie VaneimerenSioux Falls$4K
- Sara NewmanSioux Falls$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.